With much interest we read the systematic review from Stirman et al 1 about new psychotherapies for mood and anxiety disorders. Although the study has been well conducted, we think the authors have not suf ciently answered the question of whether we actually need new psychotherapies.
New Psychotherapies for Mood and Anxiety Disorders: Necessary Innovation or Waste of Resources?
Dear Editor:
With much interest we read the systematic review from Stirman et al 1 about new psychotherapies for mood and anxiety disorders. Although the study has been well conducted, we think the authors have not suf ciently answered the question of whether we actually need new psychotherapies.
On the one hand, there is a clear need for better treatments, as mood and anxiety disorders constitute a considerable burden for patients and society. Further, modelling studies have shown that current treatments can reduce only one-third of the disease burden of depression and less than one-half of anxiety disorders, even in optimal conditions. 2 However, there are already dozens of different types of psychotherapy for mood and anxiety disorders, and there is very little evidence that the effects of treatments differ signi cantly from each other. In depression, we found that interpersonal psychotherapy is somewhat more effective than other therapies, 3 but differences were very small (Cohen's d < 0.21) and the clinical relevance is not clear. In the eld of anxiety disorders, there is evidence that relaxation is less effective than cognitive-behavioural therapy, but there is very little evidence for signi cant differences between other therapies. We want to suggest, therefore, that the eld stops with developing new psychotherapies for mood and anxiety disorders unless the developers can convince nancers of research to conduct a well-powered comparative study that shows that this therapy is indeed more effective than existing therapies. In the meantime, the eld should focus on the real problems that limit the contribution of therapies to the reduction of disease burden, including the large number of patients who do not respond to any treatment, the patients who still have considerable residual symptoms after successful treatments, and patients who relapse. But there are good reasons why the eld should not stop attempting to develop new psychotherapies. As Dr Cuijpers and Dr van Straten make clear, we need ways to address lack of response, residual symptoms, and relapse rates associated with existing treatments. Other than sequencing or combined existing treatments, or attempting to match treatments to patient characteristics, the development of new psychotherapies that target nonresponders, residual symptoms, and (or) relapse is the
